Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
MWN-AI** Summary
Opus Genetics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its Supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75%, aimed at treating presbyopia—a common age-related condition that impacts near-vision clarity in adults over 45 years old. This FDA acceptance is a significant milestone for Opus, as it could potentially offer an innovative pharmacologic treatment option for the approximately 90% of U.S. adults affected by this condition.
Phentolamine ophthalmic solution 0.75% is designed to enhance near vision while maintaining distance vision by modulating pupil diameter for up to 20 hours through a non-invasive application that avoids the involvement of the ciliary muscle. The sNDA submission is backed by data from two pivotal Phase 3 clinical trials, VEGA-2 and VEGA-3, both of which showed positive efficacy results without any serious adverse events linked to the treatment. Results from the VEGA-3 trial are set to be presented at upcoming ophthalmology conferences in April and May 2026, showcasing the investigational treatment's potential.
The formulation, currently approved for treating pharmacologically induced mydriasis, demonstrates Opus Genetics' commitment to expanding its application in various ophthalmic indications. The company has a global licensing agreement with Viatris for the development and commercialization of the solution in the U.S. Opus Genetics, based in Research Triangle Park, N.C., is focused on developing gene therapies aimed at restoring vision for patients with inherited retinal diseases, with an expanding pipeline that highlights its innovative approach to eye health care.
MWN-AI** Analysis
Opus Genetics' recent announcement about the FDA's acceptance of its supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% marks a significant turning point for the company and the broader ophthalmic market. As a clinical-stage biopharmaceutical entity focused on addressing vision-related disorders, the company's potential expansion into treating presbyopia—a common degenerative condition affecting nearly 90% of adults over 45—could provide a lucrative opportunity.
Investors should closely monitor the upcoming PDUFA goal date of October 17, 2026. Positive outcomes could not only enhance Opus Genetics' market position but also catalyze an uptick in share prices. The dual advantage of offering a pharmacologic solution for presbyopia while maintaining distance vision is a notable selling point that could capture significant market share currently dominated by reading glasses and other corrective lenses.
Moreover, the supportive data from the pivotal Phase 3 trials (VEGA-2 and VEGA-3), which demonstrated favorable safety and efficacy profiles, strengthens the outlook. Investors may also find it reassuring that phentolamine is already approved for other ophthalmic uses, providing a solid pre-existing framework for commercialization and marketing.
Potential risks remain, however, including dependence on successful trial results, market competition, and regulatory hurdles that could impede full market entry. Furthermore, while partnerships—such as the global licensing agreement with Viatris—can bolster commercialization efforts, they may also dilute returns due to shared revenue models.
In conclusion, while Opus Genetics showcases promising innovations in treating presbyopia, investors should weigh the favorable prospects against inherent risks. Active engagement with research outcomes, market dynamics, and regulatory updates is critical as the company navigates this pivotal phase.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. The FDA has assigned a PDUFA goal date of October 17, 2026.
Presbyopia is an age-related condition that affects the ability to focus on near objects and impacts millions of adults worldwide, often requiring reading glasses or other visual aids. If approved, phentolamine ophthalmic solution 0.75% has the potential to offer a pharmacologic treatment option for patients seeking improved visual acuity without reliance on corrective lenses. The condition affects approximately 90% of adults in the U.S. over the age of 45.
“The FDA’s acceptance of our sNDA marks an important milestone in expanding the potential use of phentolamine ophthalmic solution as a differentiated approach to managing presbyopia,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “Phentolamine is targeted to improve near vision while preserving distance vision, with a sustained effect on pupil diameter of up to 20 hours. Our team continues to make tremendous progress in advancing our mission to bring meaningful new ophthalmic treatment options to patients.”
Phentolamine ophthalmic solution 0.75% is a preservative-free, topical ophthalmic formulation designed to modulate pupil dynamics and improve visual acuity through a sympatholytic mechanism of action that avoids engaging the ciliary muscle.
The sNDA is supported by data from a pivotal Phase 3 clinical program, including two trials, VEGA-2 and VEGA-3. Both trials demonstrated positive efficacy results for this investigational non-invasive treatment option for presbyopia, meeting the primary and all key secondary endpoints, with no treatment-related serious adverse events. The Company intends to have data from VEGA-3 presented at the American Society of Cataract and Refractive Surgery (ASCRS) meeting in April 2026 in Washington, D.C. and the Association for Research in Vision and Ophthalmology (ARVO) meeting in May 2026 in Denver, Colorado. Phentolamine ophthalmic solution 0.75% is also being investigated across additional ophthalmic indications.
Ryzumvi ® (phentolamine ophthalmic solution 0.75%) is currently approved in the U.S. for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents, and is the only commercially available FDA-approved product for this use. The sNDA seeks to expand the indication to include presbyopia.
Opus Genetics and Viatris, Inc. (Viatris) (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants exclusive rights to Viatris to commercialize phentolamine ophthalmic solution 0.75% in the U.S.
RYZUMVI® IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.
Adverse Reactions
The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).
Please see Full Prescribing Information.
About Phentolamine Ophthalmic Solution 0.75%
Phentolamine ophthalmic solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop. It works by blocking alpha-1 adrenergic receptors on the iris dilator muscle. Phentolamine ophthalmic solution 0.75% is designed to reduce pupil diameter through a sympatholytic mechanism of action that avoids engaging the ciliary muscle, potentially reducing risks such as retinal tears or detachment associated with parasympathomimetic agents. Phentolamine ophthalmic solution 0.75% is currently approved in the U.S. for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents; and has successfully completed a Phase 3 program for presbyopia (VEGA clinical program), and is being evaluated in a Phase 3 program for the treatment of dim (mesopic) light vision disturbances (sometimes referred to as DLD) after keratorefractive surgery (LYNX clinical program).
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine ophthalmic solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to the clinical development, clinical results, preclinical data, and future plans for Phentolamine ophthalmic solution 0.75% and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, our subsequent Quarterly Reports on Form 10-Q, and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
FAQ**
What are the potential market implications for Opus Genetics Inc. IRD if the FDA approves the sNDA for phentolamine ophthalmic solution 0.75% for presbyopia treatment by the PDUFA goal date of October 17, 2026?
How does the partnership with Viatris influence the commercialization strategy for Opus Genetics Inc. IRD’s phentolamine ophthalmic solution 0.75%?
Can you elaborate on how the results from the VEGA trials support the effectiveness of phentolamine ophthalmic solution 0.75% and how they could impact Opus Genetics Inc. IRD’s future development plans?
What steps is Opus Genetics Inc. IRD taking to address safety concerns raised in the use of phentolamine ophthalmic solution 0.75%, especially regarding patients with active ocular inflammation?
**MWN-AI FAQ is based on asking OpenAI questions about Ocuphire Pharma Inc Com (NASDAQ: OCUP).
NASDAQ: OCUP
OCUP Trading
-13.68% G/L:
$1.17 Last:
676,715 Volume:
$1.33 Open:
